Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

Lancet

Volumn 358, Issue 9275, 2001, Pages 24-29

  Gillmore, Julian D ^a   Lovat, Laurence B ^a   Persey, Malcolm R ^a   Pepys, Mark B ^a   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; AMYLOID P COMPONENT; ANTIBIOTIC AGENT; CHLORAMBUCIL; COLCHICINE; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; FAMILIAL MEDITERRANEAN FEVER; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SCINTIGRAPHY; SURVIVAL; TREATMENT OUTCOME;

EID: 0035822274     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05252-1     Document Type: Article

References (36)

1. Amyloidosis
2. Rapid automated enzyme immunoassay of serum amyloid A
3. A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay
4. A particle-enhanced reagent for the immunonephelometric determination of serum amyloid A (SAA)
5. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum
6. The first international standard for serum amyloid A protein (SAA): Evaluation in an international collaborative study
7. Secondary systemic amyloidosis: Response and survival in 64 patients
8. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis
9. Treatment of amyloidosis and the rheumatologist: State of the art and perspectives for the future
10. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis
11. Amyloidosis in juvenile chronic polyarthritis
12. Death in juvenile rheumatoid arthritis
13. Chronic dialysis in patients with systemic amyloidosis: The experience in Northern Italy
14. Amyloidosis
15. Behçet's disease and AA-type amyloidosis
16. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics
17. Complete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndrome
18. Clinical and therapeutic aspects of AA amyloidosis
19. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component
20. 123I-labeled serum amyloid P component
21. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression
22. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: Regression of visceral amyloid following liver transplantation
23. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value
24. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
25. 123I serum amyloid P component scintigraphy in 484 patients
26. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo
27. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis
28. 123I-labeled serum amyloid P component
29. Comparison of histology with SAP scintigraphy for evaluation of amyloidosis
30. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology
31. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
32. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen a-chain variant in an English family
33. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
34. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis
35. The Lumleian lecture. C-reactive protein and amyloidosis: From proteins to drugs?
36. A primed state exists in vivo following histological regression of amyloidosis